Transcriptomic profiling of meningiomas reveals SMARCB1 mutation-driven immunosuppression via IL-17/CSF1 axis

This study integrates bulk RNA-seq data from 13 human meningioma samples and 1 control sample to investigate the role of SMARCB1 mutations in shaping an immunosuppressive tumor microenvironment. We identified a 14-gene signature characterizing the immunogenic subtype and proposed a mechanistic link between SMARCB1 deficiency, IL-17 signaling activation, and CSF1-mediated recruitment of CD163+ tumor-associated macrophages (TAMs). The dataset includes primary and recurrent meningiomas across WHO grades (1-3), with paired clinical metadata (e.g., WHO grade, recurrence status, SMARCB1 mutation status). Findings may guide future immunotherapy strategies for meningioma.